SCHEMBL14814987

SCHEMBL14814987

FC(F)(F)c1ccnc(N2CCN3CCC(Oc4ccc(Cl)cn4)C3C2)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ADRB1 P08588 1/20 0.40
▸ SCD O00767 2/20 0.38
▸ DPP4 P27487 1/20 0.38
▸ DPP7 Q9UHL4 1/20 0.38
▸ ACACB O00763 2/20 0.38
▸ LIPG Q9Y5X9 1/20 0.38
▸ HRH3 Q9Y5N1 1/20 0.37
▸ TACR3 P29371 1/20 0.37
▸ LIPE Q05469 1/20 0.36
▸ SCN9A Q15858 1/20 0.36
▸ CYP17A1 P05093 1/20 0.36
▸ FFAR4 Q5NUL3 1/20 0.36
▸ CHRM2 P08172 1/20 0.35
▸ CHRM1 P11229 1/20 0.35
▸ CHRM3 P20309 1/20 0.35
▸ KDM4E B2RXH2 2/20 0.35
▸ CYP2D6 P10635 1/20 0.35
▸ L3MBTL1 Q9Y468 1/20 0.35
▸ PIK3CD O00329 1/20 0.34
▸ DRD2 P14416 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14814988 1.00 ADRB1 (0.40) ADRB1SCDDPP4DPP7ACACB
SCHEMBL14815145 0.87 TACR3 (0.47) DPP4DPP7LIPGHRH3TACR3
SCHEMBL14815146 0.87 TACR3 (0.47) DPP4DPP7LIPGHRH3TACR3
SCHEMBL14814829 0.81 ACACB (0.37) DPP4DPP7ACACBHRH3
SCHEMBL14814827 0.81 ACACB (0.37) DPP4DPP7ACACBHRH3
SCHEMBL14816121 0.76 KDM4E (0.44) KDM4EL3MBTL1
SCHEMBL14816189 0.76 KDM4E (0.44) KDM4EL3MBTL1
SCHEMBL14815181 0.76 MGLL (0.48) LIPESCN9AKDM4E
SCHEMBL14815083 0.76 MGLL (0.48) LIPESCN9AKDM4E
SCHEMBL14815085 0.76 MGLL (0.48) LIPESCN9AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2013049164-A1 SUBSTITUTED OCTAHYDROPYRROLO[1,2-a]PYRAZINES AS CALCIUM CHANNEL BLOCKERS ABBVIE INC. (US) 2013-04-04 — — WO claimed
US-20130085142-A1 SUBSTITUTED OCTAHYDROPYRROLO[1,2-a]PYRAZINES AS CALCIUM CHANNEL BLOCKERS ABBVIE INC. (US) 2013-04-04 — — US claimed
US-8669255-B2 Substituted octahydropyrrolo[1,2-a]pyrazines as calcium channel blockers ABBVIE INC. (US) 2014-03-11 — — US disclosed
US-20130085142-A1 SUBSTITUTED OCTAHYDROPYRROLO[1,2-a]PYRAZINES AS CALCIUM CHANNEL BLOCKERS ABBVIE INC. (US) 2013-04-04 — — US disclosed
WO-2013049164-A1 SUBSTITUTED OCTAHYDROPYRROLO[1,2-a]PYRAZINES AS CALCIUM CHANNEL BLOCKERS ABBVIE INC. (US) 2013-04-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130085142-A1 SUBSTITUTED OCTAHYDROPYRROLO[1,2-a]PYRAZINES AS CALCIUM CHANNEL BLOCKERS CACNA1C, CACNA1E, CACNA1D ADRB1 116/4885SCD 4606/4885DPP4 578/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback